drugset / Trial / NCT07645300
LOw DosE Spironolactone, chlorThAlidone oR Combination in CKD Trial
Phase 2
Not yet recruiting
160 enrolled
VA Office of Research and Development
Michael E. DeBakey VA Medical Center · collabVA Salt Lake City Health Care System · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this research is to gather information on the safety and effectiveness of spironolactone and chlorthalidone for treatment of high blood pressure in patients with moderate to advanced CKD. Both drugs have been approved by the Food and Drug Administration (FDA) for the treatment of high blood pressure since 1960.
Timeline
- Start
- 2026-10-01
- Primary completion
- 2032-03-31
- Completion
- 2032-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Chlorthalidone | Other / unclassified | — | — |
| Subject | Spironolactone | Small molecule | — | — |